Table 2B.
Inflammatory profile adjusted for confounding
| Controlled for weight | Controlled for HbA1C | Controlled for UACR | Controlled for eGFR | |||||
|---|---|---|---|---|---|---|---|---|
| Group difference** | P‐value** | Group difference* | P‐value* | Group difference** | P‐value** | Group difference | P‐value* | |
| IFN‐y | 7.0% (−33.3, 71.6) | .780 | −21.3% (−49.2, 22.0) | .284 | −22.8% (−51.1, 21.9) | .267 | −20.1% (−48.6, 24.1) | .317 |
| IL‐10 | −2.4% (−25.0, 27.) | .857 | −9.9% (−28.6, 13.5) | .376 | −8.2% (−28.3, 17.4) | .495 | −8.4% (−27.7, 15.9) | .465 |
| IL‐6 | −18.0% (−36.4, 5.7) | .125 | −25.7% (−39.7, –8.4) | .005 | −24.1% (−40, −4.1) | .021 | −23.8% (−39.2, −4.5) | .018 |
| IL‐8 | −2.5% (−19.4, 18.1) | .799 | −7.9% (−22.2, 9.1) | .343 | −4.6% (−19.9, 13.6) | .595 | −8.1% (−22, 8.2) | .308 |
| TNF‐a | 9.1% (−0.4, 19.4) | .060 | 3.4% (−4.5, 12.0) | .408 | 3.9% (−4.3, 12.8) | .366 | 3.2% (−4.6, 11.7) | .431 |
| CD206 | −2.0% (−10.1, 6.8) | .639 | −5.7% (−12.7, 1.8) | .135 | −0.9% (−6.6, 5.1) | .755 | −2.2% (−7.8, 3.8) | .465 |
| CD163 | 1.3% (−5.0, 7.9) | .699 | −1.9% (−7.6, 4.1) | .525 | −3.6% (−10.7, 4) | .340 | −5.6% (−12.5, 1.8) | .137 |
Models have been adjusted for baseline values of the given outcome, and adjusted for: (i) change in weight; (ii) change in HbA1C; (iii) change in UACR; and (iv) change in eGFR during trial. IFN = interferon; IL = interleukin; TNF = tumour necrosis factor; UACR = urine albumin/creatinine ratio.
*P < 0.05; **P < 0.01.